http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#Head
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#assertion
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#provenance
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#pubinfo
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#assertion
http://purl.obolibrary.org/obo/DOID_3908
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_3908
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB05578
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association
http://www.w3.org/2000/01/rdf-schema#label
cyramza r as a single agent or in combination with paclitaxel for treatment of advanced or metastatic gastric or gastro esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine or platinum containing chemotherapy 1 1 in combination with docetaxel for treatment of metastatic non small cell lung cancer with disease progression on or after platinum based chemotherapy patients with egfr or alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving cyramza 1 2 in combination with folfiri for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine 1 3 as a single agent for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of 4 ng ml and have been treated with sorafenib 1 4 cyramza r cyramza in combination with docetaxel is indicated for the treatment of patients with metastatic non small cell lung cancer nsclc with disease progression on or after platinum based chemotherapy patients with epidermal growth factor receptor egfr or anaplastic lymphoma kinase alk genomic tumor aberrations should have disease progression on fda approved therapy for these aberrations prior to receiving cyramza cyramza in combination with folfiri irinotecan folinic acid and fluorouracil is indicated for the treatment of patients with metastatic colorectal cancer mcrc with disease progression on or after prior therapy with bevacizumab oxaliplatin and a fluoropyrimidine
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB05578
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#provenance
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#pubinfo
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#sig
http://purl.org/nanopub/x/hasSignature
NHdqiLdcFb7j9YujwVJrDrMfkUPvXCqcenz4XiQ0UEXXvgHk67/940GvpvzqdPUU5970D3wh6hrbx9v2xzNIDpVmcj5gWGIA7eMNC8+4XEfHsCHs3N04r8Ir1kM+2NeoaNgy5d2HjIw7YReC6IrEkMGkoxDBwfyq3mu/L/lfhsI=
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg
http://purl.org/dc/terms/created
2021-07-03T14:43:26.175+02:00
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAmIAR0YhBPgecXe7cX3QuOLko2qxUEy6OwuM5TaO4YBg
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs